Table 1.
Odds Ratios (ORs) and 95% confidence intervals (CIs) for non-Hodgkin lymphoma (NHL) and NHL subtypes associated with average intensity of solvent exposure, San Francisco Bay Area, California.
| Total | Controlsa N=2094 n (%) |
Total NHLa N=1262 n (%) |
OR (95 % CI)b | DLCL N=497 n (%) |
OR (95 % CI)b | FL N=340 n (%) |
OR (95 % CI)b | CLL/SLL N=148 n (%) |
OR (95 % CI)b | Other NHL N=277 n (%) |
OR (95 % CI)b |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvents | |||||||||||
| Never | 526 (25) | 344 (27) | 1.0 | 140 (28) | 1.0 | 92 (27) | 1.0 | 41 (28) | 1.0 | 71 (26) | 1.0 |
| Ever | 1568 (75) | 918 (73) | 0.95 (0.80-1.1) | 357 (72) | 0.93 (0.74-1.2) | 248 (73) | 1.1 (0.79-1.4) | 107 (72) | 0.95 (0.63-1.4) | 206 (74) | 0.87 (0.64-1.2) |
| Low | 1147 (55) | 662 (52) | 0.95 (0.79-1.2) | 250 (50) | 0.89 (0.69-1.1) | 181 (53) | 1.0 (0.77-1.4) | 80 (54) | 0.97 (0.63-1.5) | 151 (55) | 0.87 (0.62-1.2) |
| Med-High | 421 (20) | 256 (20) | 0.95 (0.78-1.2) | 107 (22) | 1.1 (0.78-1.4) | 67 (20) | 1.1 (0.75-1.5) | 27 (18) | 0.90 (0.53-1.5) | 55 (20) | 0.88 (0.59-1.3) |
| Benzene | |||||||||||
| Never | 726 (35) | 479 (38) | 1.0 | 191 (38) | 1.0 | 138 (41) | 1.0 | 57 (39) | 1.0 | 93 (34) | 1.0 |
| Ever | 1368 (65) | 783 (62) | 0.93 (0.79-1.1) | 306 (62) | 0.93 (0.74-1.2) | 202 (59) | 0.90 (0.69-1.2) | 91 (61) | 0.90 (0.61-1.3) | 184 (66) | 0.95 (0.70-1.3) |
| Low | 967 (46) | 551 (44) | 0.92 (0.77-1.1) | 208 (42) | 0.89 (0.70-1.1) | 142 (42) | 0.89 (0.67-1.1) | 67 (45) | 0.93 (0.61-1.4) | 134 (48) | 0.97 (0.71-1.3) |
| Med-High | 401 (19) | 232 (18) | 0.95 (0.77-1.2) | 98 (20) | 1.0 (0.76-1.4) | 60 (18) | 0.92 (0.64-1.3) | 24 (16) | 0.84 (0.50-1.4) | 50 (18) | 0.89 (0.6-1.3) |
| Formaldehyde | |||||||||||
| Never | 839 (40) | 505 (40) | 1.0 | 201 (40) | 1.0 | 134 (39) | 1.0 | 58 (39) | 1.0 | 112 (40) | 1.0 |
| Ever | 1255 (60) | 757 (60) | 1.0 (0.87-1.2) | 296 (60) | 1.0 (0.82-1.2) | 206 (61) | 1.1 (0.85-1.4) | 90 (61) | 1.0 (0.73-1.5) | 165 (60) | 0.94 (0.73-1.2) |
| Low | 781 (37) | 485 (38) | 1.0 (0.88-1.2) | 202 (41) | 1.1 (0.88-1.4) | 123 (36) | 1.0 (0.78-1.3) | 59 (40) | 1.1 (0.73-1.6) | 101 (36) | 0.92 (0.69-1.2) |
| Med-High | 474 (23) | 272 (22) | 1.0 (0.81-1.2) | 94 (19) | 0.85 (0.65-1.1) | 83 (24) | 1.2 (0.87-1.6) | 31 (21) | 0.99 (0.63-1.6) | 64 (23) | 0.99 (0.71-1.4) |
a
The number of participants may vary because of missing data
b
Age, sex, education, race, and ethnicity adjusted values; DLCL, diffuse large-cell and immunoblastic large-cell; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma.